Literature DB >> 25503828

Inhibition of i-NOS but not n-NOS protects rat primary cell cultures against MPP(+)-induced neuronal toxicity.

Monika J Brzozowski1, Peter Jenner, Sarah Rose.   

Abstract

Nitrative stress is a key component of the pathogenic process in Parkinson's disease (PD), but the relative roles of constitutive neuronal nitric oxide synthase (n-NOS) and inducible nitric oxide synthase (i-NOS) in glial cells remain unresolved. We have investigated the effects of a range of concentrations of the selective n-NOS inhibitor ARR17477, and the selective i-NOS inhibitor 1400W, on MPP(+)-induced cell death in foetal ventral mesencephalic (VM) dopaminergic cultures. MPP(+) induced a loss of TH-positive neurones accompanied by an increase in immunoreactivity for GFAP and OX-6 as markers of astrocytes and activated microglia, respectively, and induced i-NOS immunoreactivity. Unexpectedly, MPP(+) treatment did not induce 3-NT immunoreactivity in the cultures. ARR17477 and 1400W alone had no effect on the number of TH-positive cells or on the number of GFAP or OX-6 positive cells. ARR17477 did not prevent the MPP(+)-induced decrease in TH-positive neurones and had no effect on the increased number of GFAP- and OX-6-positive cells. By contrast, 1400W caused a concentration-dependent preservation of TH-positive neurones in the presence of MPP(+). It also significantly reduced the number of OX-6-immunoreactive cells and there was a small reduction in GFAP immunoreactivity. The results suggest a major role for i-NOS-mediated nitrative stress in microglia in MPP(+)-induced dopaminergic cell death and this may have important implications for developing neuroprotective strategies for PD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25503828     DOI: 10.1007/s00702-014-1334-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  37 in total

1.  Structural basis for the specificity of the nitric-oxide synthase inhibitors W1400 and Nomega-propyl-L-Arg for the inducible and neuronal isoforms.

Authors:  Roman Fedorov; Elisabeth Hartmann; Dipak K Ghosh; Ilme Schlichting
Journal:  J Biol Chem       Date:  2003-09-03       Impact factor: 5.157

2.  On the selectivity of 7-nitroindazole as an inhibitor of neuronal nitric oxide synthase.

Authors:  A Reiner; Y Zagvazdin
Journal:  Trends Pharmacol Sci       Date:  1998-09       Impact factor: 14.819

3.  The effect of nNOS inhibitors on toxin-induced cell death in dopaminergic cell lines depends on the extent of enzyme expression.

Authors:  Monika J Brzozowski; Susana Lopez Alcantara; Mahmoud M Iravani; Sarah Rose; Peter Jenner
Journal:  Brain Res       Date:  2011-06-13       Impact factor: 3.252

4.  Compartmental organization and chemical profile of dopaminergic and GABAergic neurons in the substantia nigra of the rat.

Authors:  T González-Hernández; M Rodríguez
Journal:  J Comp Neurol       Date:  2000-05-22       Impact factor: 3.215

5.  A high percentage yield of tyrosine hydroxylase-positive cells from rat E14 mesencephalic cell culture.

Authors:  K Shimoda; Y Sauve; A Marini; J P Schwartz; J W Commissiong
Journal:  Brain Res       Date:  1992-07-24       Impact factor: 3.252

6.  Nitric oxide synthase inhibitors protect against rotenone-induced, oxidative stress mediated parkinsonism in rats.

Authors:  K S Madathil; S S Karuppagounder; R Haobam; M Varghese; U Rajamma; K P Mohanakumar
Journal:  Neurochem Int       Date:  2013-01-23       Impact factor: 3.921

7.  Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.

Authors:  Hijiri Watanabe; Yasuko Muramatsu; Rumiko Kurosaki; Mari Michimata; Mitsunobu Matsubara; Yutaka Imai; Tsutomu Araki
Journal:  Eur Neuropsychopharmacol       Date:  2004-03       Impact factor: 4.600

8.  Nitration of soluble proteins in organotypic culture models of Parkinson's disease.

Authors:  Trine R Larsen; Ann-Sofi Söderling; Kenneth Caidahl; Peter Roepstorff; Jan Bert Gramsbergen
Journal:  Neurochem Int       Date:  2007-08-19       Impact factor: 3.921

9.  The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease.

Authors:  Belen Joglar; Jannette Rodriguez-Pallares; Ana Isabel Rodriguez-Perez; Pablo Rey; Maria Jose Guerra; Jose Luis Labandeira-Garcia
Journal:  J Neurochem       Date:  2009-02-20       Impact factor: 5.372

10.  Nitric oxide synthase and neuronal vulnerability in Parkinson's disease.

Authors:  S Hunot; F Boissière; B Faucheux; B Brugg; A Mouatt-Prigent; Y Agid; E C Hirsch
Journal:  Neuroscience       Date:  1996-05       Impact factor: 3.590

View more
  3 in total

1.  Reduced Retinal Degeneration in an Oxidative Stress Organ Culture Model through an iNOS-Inhibitor.

Authors:  Ana M Mueller-Buehl; Teresa Tsai; José Hurst; Carsten Theiss; Laura Peters; Lisa Hofmann; Fenja Herms; Sandra Kuehn; Sven Schnichels; Stephanie C Joachim
Journal:  Biology (Basel)       Date:  2021-04-28

2.  Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress.

Authors:  Camille B Carroll; Richard K H Wyse
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

3.  Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia.

Authors:  Marvin Heimke; Florian Lenz; Uta Rickert; Ralph Lucius; François Cossais
Journal:  Cells       Date:  2022-10-02       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.